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ABSTRACT
The NF-B is found in almost all animal cell types
and is involved in a myriad of cellular responses.
Aberrant expression of NF-B has been linked to
cancer, inflammatory diseases and improper devel-
opment. Little is known about transcriptional regula-
tion of the NF-B family member gene RelA/p65. Sp1
plays a key role in the expression of the RelA/p65
gene. ZBTB2 represses transcription of the gene by
inhibiting Sp1 binding to a Sp1-binding GC-box in
the RelA/p65 proximal promoter (bp, −31 to −21).
Moreover, recent studies revealed that RelA/p65 di-
rectly binds to the peroxisome proliferator-activated
receptor- coactivator1 (PGC1) to decrease tran-
scriptional activation of the PGC1 target gene
PDK4, whose gene product inhibits pyruvate dehy-
drogenase (PDH), a key regulator of TCA cycle flux.
Accordingly, we observed that RelA/p65 repression
by ZBTB2 indirectly results in increased PDK4 ex-
pression, which inhibits PDH. Consequently, in cells
with ectopic ZBTB2, the concentrations of pyruvate
and lactate were higher than those in normal cells,
indicating changes in glucose metabolism flux fa-
voring glycolysis over the TCA cycle. Knockdown
of ZBTB2 in mouse xenografts decreased tumor
growth. ZBTB2 may increase cell proliferation by re-
programming glucose metabolic pathways to favor
glycolysis by upregulating PDK4 expression via re-
pression of RelA/p65 expression.
INTRODUCTION
Among the nearly 200 different members of the POZ-
domain protein family, 48members have aC-terminal C2H2
Kru¨ppel-type zinc finger DNA-binding domain (http://btb.
uhnres.utoronto.ca). Some of the POZ-ZF proteins are
characterized as important transcription factors implicated
in cancer and development (1). We previously investigated
the biological functions of various POK family proteins,
including KR-POK, FBI-1, ZBTB5 and ZBTB2 (zinc fin-
ger and BTB domain containing 2) (2–7). While numer-
ous studies have identified ZBTB2 as part of various pro-
tein complexes (8–10), its functional characteristics remain
largely unknown. We demonstrated that ZBTB2 is a mas-
ter proto-oncoprotein that controls the expression of genes
in the p53 pathway (ARF-HDM2-p53-p21) and, in partic-
ular, is a potent transcriptional repressor of the cell cycle
arrest gene CDKN1A through inhibition of p53 and Sp1
(7). Moreover, targeting of ZBTB2 in human gastric cancer
by microRNA-149 inhibits proliferation and cell cycle pro-
gression (11), and a genome-wide association study identi-
fied ZBTB2 in a gene cluster associated with susceptibility
to chronic myeloid leukemia (12). ZBTB2 was also iden-
tified as one of the proteins that belong to the ubiquitin-
proteasome system that is required for mammalian DNA
damage checkpoint control, particularly at the G1 cell cy-
cle checkpoint (13). Interestingly, ZBTB2 was also found
to associate with the transcription cofactor CBP (14), and
ZBTB2 has also been identified as a candidate oncoprotein
having an R261W polymorphism that potentiates its mito-
genic activity in human colorectal cancers with microsatel-
lite instability (15).
NF-B family members, central mediators of the human
immune (both innate and adaptive immunity) (16–18) and
stress responses (19) are activated by various intra- and
extra-cellular stimuli such as bacteria, viruses, cytokines,
oxidative stress, growth factors and hormones (20). In par-
ticular, NF-B regulates the expression of genes controlling
apoptosis, cell adhesion, proliferation, inflammation and
tissue remodeling (21,22), and dysregulation of NF-B ac-
tivity has been linked to inflammatory disorders, autoim-
mune and metabolic diseases, as well as cancer (23–25).
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In mammalian cells, there are five NF-B family mem-
bers, RelA/p65, RelB, c-Rel, p50/p105 (NF-B1) and
p52/p100 (NF-B2). All NF-B family members contain a
structurally conserved N-terminal Rel-homology domain,
composed of 300 amino acids, that mediates DNA bind-
ing and subunit dimerization. Although all NF-B family
members bind DNA, only RelA/65, c-Rel and RelB have
a transactivation domain in their C-termini. While RelB
and c-Rel show tissue-specific expression, RelA/p65 and
p50/NF-B1 exist in a variety of cell types, and in the nu-
cleus, RelA/p65 induces numerous genes that regulate the
cellular processes mentioned above (26). Moreover, activ-
ity of the RelA/p65 subunit of the NF-B complex can be
regulated by post-translational modifications such as phos-
phorylation, acetylation and methylation (27–29).
In addition to the translocation and post-translational
modifications of NF-B in response to various stimuli,
the precise regulation of each subunit of NF-B is criti-
cal. In particular, the expression of RelA/p65 is significant
to NF-B activity because RelA/p65 is a primary subunit
of the NF-B complex expressed in almost all tissues. Al-
though post-translational modifications of RelA/p65 af-
fecting NF-B activity have been studied extensively, the
molecular mechanism on how RelA/p65 gene transcription
is regulated remains elusive. Although the RelA/p65 pro-
moter region is highly GC-rich and has many GC boxes to
which Sp1 may bind (30), little is known about how these
sites may regulate RelA/p65 expression. Previously, it was
shown that human cytomegalovirus infection increased Sp1
mRNA and protein which, in turn, may potently activate
RelA/p65 transcription through its promoter Sp1-binding
sites (31,32); these sites may also bind MDM2 to induce
RelA/p65 (33).
A key regulator of TCA cycle flux, the pyruvate de-
hydrogenase (PDH) complex that converts pyruvate into
acetyl coenzyme A (Ac-CoA), is regulated by four PDH
kinase isozymes (PDK1-4) (34). These kinases are lo-
cated in the matrix of the mitochondria and phosphory-
late and inhibit PDH complex subunits. Additionally, it
was recently shown that PGC1 (peroxisome proliferator–
activated receptor- coactivator 1), a key regulator of lipid
and glucose oxidative metabolism, increases PDK4 gene ex-
pression by binding to a putative nuclear receptor (NR)
binding site in the PDK4 promoter (35). Additionally, in
the myocardium, TNF-activated RelA/p65 binds to and
inhibits PGC1 transactivation activity, resulting in down-
regulation of PDK4 (36).
Here, we investigated the functional significance of
whether ZBTB2 regulates RelA/p65 to elicit a shift in
metabolism in highly proliferating or cancer cells through
enhanced PGC1 transcriptional activation of PDK4 and
inhibition of PDH. We demonstrate that ZBTB2 may be
a proto-oncoprotein that plays important roles in cell pro-
liferation by reprogramming metabolic pathways via tran-
scriptional regulation of RelA/p65 and indirect upregula-
tion of PDK4 expression.
MATERIALS AND METHODS
Plasmids, antibodies and reagents
To express ZBTB2 protein with a FLAG tag, a full-length
human ZBTB2 cDNA fragment was polymerase chain re-
action (PCR)-amplified from a cDNA library and cloned
into pcDNA3 vector (Invitrogen). The pcDNA3-POZ-
ZBTB2 expression vector was prepared by cloning the
ZBTB2 cDNA fragment lacking the POZ domain and re-
ported elsewhere (7). To prepare recombinant GST-POZ-
ZBTB2 and GST-ZF-ZBTB2 proteins, cDNA fragments
encoding the POZ domain (a.a. 24–117) and zinc fingers
(a.a. 254–468) were cloned into pGEX4T3 (AmershamBio-
sciences). Recombinant His-ZBTB2 full-length protein was
produced by cloning ZBTB2 cDNA into pET-21(a) expres-
sion vector (EMDMillipore) and induced expression in Es-
cherichia coli DH5 cells. To prepare the pGL2-RelA/p65-
Luc plasmid, the human RelA/p65 promoter region (bp,
−401 to +92) was PCR-amplified from human genomic
DNA isolated from human embryonic kidney HEK293
cells and cloned into the XhoI and HindIII sites of the
pGL2-basic vector. Other pGL2-RelA/p65-Luc constructs
with shorter promoter sequences were cloned in the same
way. The pGL2-RelA/p65-Luc −47-bp construct with mu-
tation at GC-box #3 (bp,−30 to−20) was prepared by site-
directed mutagenesis. The pNF-B-Luc plasmid was pur-
chased from Clontech. All plasmid constructs were veri-
fied by sequencing. Antibodies against RelA/p65, Sp1 and
PGC1 were purchased from Santa Cruz Biotechnology.
Antibodies recognizing glyceraldehyde-3-phosphate dehy-
drogenase (GAPDH) and PDK4 were purchased from
Millipore and Abcam, respectively. Most of the chemical
reagents were purchased from Sigma.
Cell culture and transcription analysis
Human HEK293 and U343 cells were cultured in Dul-
becco’s Modified Eagle Medium (Life Technologies) sup-
plemented with 10% fetal bovine serum (Invitrogen) and
1% penicillin/streptomycin (Invitrogen). To analyze tran-
scriptional regulation of the RelA/p65 promoter or pNF-
B-Luc by ZBTB2, various promoter–reporter construct
plasmids, in various combinations with pcDNA3-ZBTB2
or empty pcDNA3 vectors, were transiently transfected into
HEK293 cells using Lipofectamine Plus reagent (Invitro-
gen). The transfected cells were further cultured for 48 h,
harvested and analyzed for luciferase activity. Reporter ac-
tivity was normalized to the total protein concentration of
the cell lysates.
RNA isolation and real-time PCR quantification of mRNA
Total RNA was isolated from HEK293 and U343 cells us-
ing TRIzol reagent (Invitrogen). A cDNA pool was then
synthesized using 5 g of total RNA, oligo-dT primers
(10 pmol) and reverse transcriptase II (200 units) in a
20-l reaction volume, using a reverse transcription kit
(Promega). RT-qPCR was then performed using SYBR
Green Master Mix (Applied Biosystems) in a StepOne-
Plus real-time PCR instrument (Applied Biosystems). The
following oligonucleotide PCR primer sets were used for
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qPCR quantification of ZBTB2, RelA/p65, Sp1 and 18S
RNA: ZBTB2 forward, 5′-GATCGGATCCGATTTGGC
CAACCATGGA-3′, reverse, 5′-GATCCTCGAGAGAA
AAGGCTCCCTGGCT-3′; RelA/p65 forward, 5′-CTGC
AGTTTGATGATGAAGA-3′, reverse, 5′-TAGGCGAG
TTATAGCCTCAG-3′; Sp1 forward, 5′-GGAGAGCAAA
ACCAGCAGAC-3′, reverse, 5′-CAATGGGTGTCAGA
GTGGTG-3′; 18S RNA forward, 5′- AGTCCCTGCCCT
TTGTACACA-3′, reverse, 5′-GATCCGAGGGCCTCAC
TAAAC-3′; IL-1 forward, 5′-ATCAGTACCTCACGGC
TGCT-3′, reverse, 5′-TGGGTATCTCAGGCATCTCC-
3′; IL-6 forward, 5′-CCACACAGACAGCCACTCACC-
3′, reverse, 5′-CTACATTTGCCGAAGAGCCCTC-3′; IL-
8 forward, 5′-ATGACTTCCAAGCTGGCCGTGGCT-3′,
reverse, 5′-TCTCAGCCCTCTTCAAAAACTTCTC-3′.
Western blot analyses
HEK293 and U343 cells were harvested 48 h after trans-
fection and lysed in RIPA buffer (50-mM Tris-HCl pH
8.0, 150-mM NaCl, 2-mM ethylenediaminetetraacetic acid
(EDTA) pH 8.0, 1% Nonidet P-40, 0.5% Na-deoxycholate,
0.1% sodium dodecyl sulphate (SDS)) for 30 min on ice
and pelleted. Protein concentrations were determined us-
ing the Bio-Rad Protein Assay Dye Reagent Concentrate
(Bio-Rad). Proteins (40–60 g) were separated by SDS-
polyacrylamide gel electrophoresis (PAGE) (8–10%) and
transferred onto Immun-BlotTM polyvinylidene difluoride
membranes (Bio-Rad), and blocked with 3% bovine serum
albumin (BSA) (Sigma-Aldrich). Themembranes were then
incubated overnight at 4◦C with primary antibody, and
protein bands were detected using horseradish peroxidase-
conjugated anti-mouse or anti-rabbit secondary antibodies
(Thermo Fisher Scientific) and visualization using ECL so-
lution (Thermo Fisher Scientific).
Knockdown of endogenous ZBTB2 and RelA/p65 mRNA by
siRNA
Three siRNAs against ZBTB2 mRNA were designed
and purchased from Bioneer (Seoul, Korea): siZBTB2–
1 5′-GAUUAGAACAGGGCAUCAA(dTdT)-3′, 5′-
UUGAUGCCCUGUUCUAAUC(dTdT)-3′; siZBTB2–2
5′-CUCCACUCCCAAUGAGGUU(dTdT)-3′, 5′-AACC
UCAUUGGGAGUGGAG(dTdT)-3′ and siZBTB2–3
5′-CUCUUACACUUGAUGUACA(dTdT)-3′, 5′-UG
UACAUCAAGUGUAAGAG(dTdT)-3′. The siRNAs
against RelA/p65 mRNA were purchased from Bioneer:
siRelA/p65 5′-CCUGAGCACCAUCAACUAU(dTdT)-
3′, 5′-AUAGUUGAUGGUGCUCAGG(dTdT)-3′.
siRNAs were transfected into HEK293 and U343 cells
using the Lipofectamine RNAiMAXReagent (Invitrogen).
Purification of GST fusion proteins and GST fusion protein
pull-down assays
pGEX4T3-POZ-ZBTB2 and pGEX4T3-ZFDBD-ZBTB2
expression plasmids, encoding the ZBTB2 POZ and zinc
finger domains, respectively, were prepared as described in
the plasmid section. The pGEX4T3 (Control), pGEX4T3-
POZ-ZBTB2 and pGEX4T3-ZFDBD-ZBTB2 plasmids
were transformed into E. coli BL21 (DE3) cells and grown
for 4 h at 37◦C in standard media. After 4 h, the bacteria
were further cultured for 14 h at 18◦C with 0.2-mM iso-
propyl 1-thio--D-galactopyranoside (IPTG, Calbiochem)
to induce protein expression. E. coli was then lysed in E.
coli lysis buffer (1-mM PMSF, 2-mM EDTA, 0.2-mg/ml
lysozyme up to 1x phosphate buffered saline (PBS)) and
recombinant proteins purified by glutathione sepharose
bead affinity chromatography (GE Healthcare). The puri-
fied proteins were resolved by SDS-PAGE (12%) to quanti-
tate and assess purity. The Sp1 polypeptide was prepared
using TNT Quick-coupled Transcription/Translation Ex-
tract (Promega) containing 40 l of TNT Quick Master
Mix and 2l of [35S]-methionine for 90min at 30◦C.GSTor
GST fusion proteins bound to glutathione sepharose beads
were washed three times with cold HEMG buffer (40-mM
HEPES pH 7.9, 100-mM KCl, 0.2-mM EDTA pH 8.0, 5-
mM MgCl2, 0.1% NP-40, 10% glycerol and 1.5-mM DTT)
and collected by centrifugation at 3000 rpm at 4◦C for 3
min. GST beads or GST fusion protein beads were incu-
bated with [35S]-methionine-labeled synthetic Sp1 protein
in HEMG buffer overnight at 4◦C with shaking. The reac-
tion mixtures were then centrifuged and the pelleted precip-
itates washed three times with 1-ml coldHEMGbuffer. The
bound proteins were resolved by SDS-PAGE (8%) and the
gels then dried and exposed to X-ray film with an image-
intensifying screen (Agfa-Gevaert).
Immunoprecipitation assays
HEK293 cells were harvested 48 h after transfection with
ZBTB2- and Sp1-overexpressing vectors and lysed in RIPA
buffer (50-mM Tris-HCl pH 8.0, 150-mM NaCl, 2-mM
EDTA pH 8.0, 1% Nonidet P-40, 0.5% Na-deoxycholate,
0.1% SDS). Cell lysates were pre-cleared, and the super-
natants were incubated with anti-ZBTB2 or anti-Sp1 anti-
bodies on a rotating platform at 4◦C for 15 h. After incuba-
tion, the cell lysates and antibody complexes were incubated
with protein A-sepharose fast flow beads for 4 h at 4◦C.
The beads were then washed three times with PBS, collected
and suspended in equal volumes of 5x SDS loading buffer.
Immunoprecipitated proteins were separated by 8% SDS-
PAGE, transferred to membranes, and western blot, us-
ing the appropriate antibodies, was performed as described
above.
Oligonucleotide pull-down assays
HEK293 cells were transfected with increasing amounts of
pcDNA3-ZBTB2, cultured for 48 h and lysed in HKMG
buffer (10-mM HEPES pH 7.9, 100-mM KCl, 5-mM
MgCl2, 10% glycerol, 1-mM dithiothreitol, 0.5% NP-40).
Cell lysates were then incubated with 1 g of biotiny-
lated double-stranded oligonucleotide (GC-box #3, GC-
box #7, GC-box #12) at 4◦C overnight. The sequences of
the oligonucleotides were as follows (only sense strands
are shown): GC-box #3, 5′-CCCTGCGCGGGGCGGG
CGGCCGCAG-3′; GC-box #7, 5′-CTCCAGGCGGGG
CCGGGACCCGGGA-3′; GC-box #12, 5′-CACTTGCT
CCCGGCCCCTGCGCCGG-3′. Both forward and reverse
oligonucleotides were incubated with 10x reaction buffer
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(3) (500-mM Tris-HCl pH 8.0, 100-mM MgCl2, 1000-mM
NaCl) at 95◦C for 5 min. After incubation, the tempera-
ture was gradually reduced to room temperature. To col-
lect DNA-bound proteins, the mixtures were incubated
overnight with streptavidin agarose beads (Thermo Scien-
tific), washed with PBS buffer and precipitated by centrifu-
gation. The precipitate was then analyzed by western blot as
described above, using anti-SP1 or anti-ZBTB2 antibodies.
Quantitative chromatin immunoprecipitation (qChIP) PCR
and ChIP-reChIP assays
HEK293 cells were transfected with pcDNA3 or pcDNA3-
ZBTB2, grown for an additional 48 h and treated with
formaldehyde (final concentration 1%) to cross-link pro-
teins to DNA, followed by cell lysis in RIPA buffer. Chro-
matin was sheared three times (amplitude: 50%; cycle:
0.5; sec: 30 s) by sonication (Bioruptor, Diagenode) and
the supernatant then incubated with specific antibodies
at 4◦C overnight. The next day, the mixture was incu-
bated with salmon sperm DNA/protein-A agarose beads
at 4◦C for 3 h. The beads were then collected, washed
with PBS and eluted with elution buffer (1% SDS, 0.1-
M NaHCO3). Input and immunoprecipitated chromatin
were then incubated with 5-M NaCl at 65◦C for 4 h to
reverse crosslinks. After incubation, the temperature was
gradually reduced to room temperature. To precipitate the
DNA, phenol/chloroform/isoamyl alcohol (Calbiochem)
was added and the DNA pellet obtained by centrifuga-
tion. As a negative control for the qChIP assays, IgG
was used. To amplify the promoter regions, PCR reac-
tions of the immunoprecipitated DNA were carried out
using the following sets of oligonucleotide primers: GC-
box #3 region within the RelA/p65 promoter, forward, 5′-
CGAGGCGCGCACTTGGCCCCGAC-3′, reverse, 5′-CC
GTCGCGTCACTGCCCGGAATC-3′; NR binding site
within the PDK4 promoter, forward, 5′-AATGAGCACG
CGGAGTCCAAACTCTT-3′, reverse, 5′-CAAGCTGG
GCTTAAGATTAGCCTCTT-3′. PCR was performed us-
ing the following cycling conditions: denaturation at 94◦C
for 5 min, followed by 40 cycles of 94◦C for 30 s, 55◦C for 30
s, 72◦C for 35 s and a final extension reaction at 72◦C for 5
min, using a GeneAmp PCR system 9700 (Applied Biosys-
tems).
For ChIP-reChIP assays of Sp1 binding to the RelA/p65
proximal promoter, the first chromatin immunoprecipitates
by an anti-ZBTB2 antibody were diluted 10 times with
buffer (15-mM Tris–HCl pH 8.1, 1% Triton X-100, 1-mM
EDTA,150-mM NaCl) and re-immunoprecipitated using
an anti-Sp1 antibody. Negative control of ChIP assays was
carried out using a rabbit IgG antibody.
Electrophoretic mobility shift assays
The sequences of the three 32P-labeled GC-box probes
of the RelA/p65 promoter are described below. Elec-
trophoretic mobility shift assay (EMSA) was performed
by incubating with recombinant GST-ZFDBD-ZBTB2
protein with the following probes (only the sequences of the
top strands are shown). GC-box #3, 5′-GATCTTTCCC
TGCGCGGGGCGGGCGGCCGCAGCCC-3′; GC-box
#7, 5′-GATCACCCTCCAGGCGGGGCCGGGACCC
GGGAGCT-3′; GC-box #12, 5′-GATCGTGCACTT
GCTCCCGGCCCCTGCGCCGGGCG-3′. The probes
were labeled by the addition of Klenow enzyme and 32P-
-[dATP], followed by purification using Sephadex G-25
columns. Binding reactions were performed at room tem-
perature for 30 min in 5x binding buffer (50-mM HEPES
pH 7.9, 300-mM KCl, 50% glycerol, 10-mM DTT and
1% BSA) containing recombinant GST-ZFDBD-ZBTB2
protein or recombinant Sp1 protein (Enzo Life Sciences)
and labeled probe (50 000 cpm). Where indicated, an
antibody against Sp1 was also added. To demonstrate the
specificity of the protein–DNA complexes, a large excess
of an unlabeled (‘cold’) oligonucleotide containing the Sp1
binding GC-boxes #3, #7 and #12 was added before the
labeled probes to compete for Sp1 binding. To investigate
competitive binding between Sp1 and ZBTB2, the probe
was incubated with recombinant Sp1 and increasing
amounts of GST-ZFDBD-ZBTB2 protein.
DNase I footprinting assays
To identify Sp1- or ZBTB2-binding sites, the RelA/p65
proximal promoter (246 bp) was cloned into the pcDNA3
vector, digested with EcoRI and labeled with Klenow frag-
ment and 32P--[dATP] (PerkinElmer). The labeled plas-
mid was then digested with a second restriction enzyme,
BamHI, separated by 4.5% PAGE, and the labeled pro-
moter fragment then isolated by electro-elution using a
Gebaflex electro-elution tube (GENTAUR). Sp1 (100, 300,
900 ng) or ZBTB2 (1, 3, 9 g) was mixed in binding buffer
(50-mM HEPES pH 7.9, 300-mM KCl, 50% glycerol, 10-
mM ZnCl2, 10-mM DTT) and incubated at room temper-
ature for 10 min. The 32P-labeled RelA/p65 promoter frag-
ment was mixed with a pre-incubated mixture containing
recombinant Sp1 or ZBTB2 and incubated for an addi-
tional 20 min at room temperature. A 20-l aliquot of di-
luted DNase I (1:500) was then added, incubated for 2 min,
and the DNase I digestion reaction stopped by adding 320
l of stop solution (20-mM Tris-Cl pH 8.0, 20-mM EDTA
pH 8.0, 250-mM NaCl, 0.5% SDS, 10-mg/ml yeast tRNA,
20-mg/ml proteinase K). The mixture was extracted with
phenol/CHCl3 and precipitated by the addition of 0.1 vol-
umes 3-M sodium acetate and 2.5 volumes ethanol. Cen-
trifuged pellets were resuspended in 10 l of distilled water
and 10 l of formamide loading buffer (Fisher Scientific).
The digested DNA (20 000 cpm) mixtures were separated
by 6% polyacrylamide gels containing 7-M urea (Duchefa
Biochemie). An autoradiogram was obtained by exposing
the dried gel to X-ray film (FUJIFILM) overnight at−70◦C
with an image enhancing screen (Kodak).
Cytosolic and nuclear protein fractionation
HEK293 cells were transfected with pcDNA3-ZBTB2
and/or pcDNA3-Sp1 expression vectors and grown for
an additional 48 h. Cells were lysed by buffer A (10-mM
HEPES pH 7.9, 1.5-mMMgCl2, 10-mMKCl, 1-mMDTT,
0.2-mM PMSF, 0.1% NP-40) and incubated on ice for 15
min. After centrifugation at 850 x g for 10 min, the super-
natants of cell lysates were collected (cytoplasmic fractions)
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and pellets were resuspended in buffer A* (10-mMHEPES
pH 7.9, 1.5-mMMgCl2, 10-mMKCl, 1-mMDTT, 0.2-mM
PMSF). After centrifugation at 1500 x g for 10 min, the pel-
lets were resuspended with buffer B (20-mM HEPES pH
7.9, 1.5-mM MgCl2, 25% glycerol, 0.42-M NaCl, 0.2-mM
EDTA, 1-mM DTT, 0.2-mM PMSF) and incubated on ice
for 30min. The nuclear fractions were then collected by cen-
trifugation at 13 000 rpm for 10 min. Final pellets contain-
ing nuclei were resuspended for western blot.
PDH activity assays
HEK293 and U343 cells were transfected with pcDNA3 or
pcDNA3-ZBTB2 expression plasmid, harvested 48 h after
transfection and resuspended in PBS. Cells were lysed by
sonication (Bioruptor) (amplitude: 50%, cycle: 0.5, 5 times).
Twenty microliter of the cell lysates was then placed in 96-
well plates followed by the addition of 25-mM oxaloacetate
and DTNB (5–5′-dithiobis(2-nitrobenzoic acid)) and 165-
l reaction assay mixture (0.25-MTris-HCl pH 8.0, 40-mM
-NAD+, 32.5-mM CoA-SH, 20-mM TPP, 56-mM pyru-
vate, 1-MMgCl2, 100-mMDTT, 1-l citrate synthase (0.25
unit)). After 10-min incubation, the reaction mixtures were
analyzed using a VERSAMAX microplate reader (Molec-
ular Devices) (412 nm, run time: 20 min, interval: 15 s).
Analysis of lactate concentration
HEK293 and U343 cells were transfected with pcDNA3 or
pcDNA3-ZBTB2 expression plasmid and harvested 48 h af-
ter transfection. Lactate concentration was determined by
measuring absorbance at 570 nm using a colorimetric assay
kit (Sigma).
Preparation of recombinant expressing adenovirus siRNA
against ZBTB2 mRNA
To prepare recombinant adenovirus expressing
siRNA against ZBTB2 mRNA, annealed shRNA
(sense: 5′-GATC-CAGGTGAATCGGACAAATATT-
TTCAAGAGA(loop)-TATTTGTCCGATTCACCTGTT-
TTTTTGGAA(loop)-A-3′), antisense: 5′-GATC-TTCC
AAAAA(loop)-AACAGGTGAATCGGACAAATA-
TCTCTTGAA(loop)-AATATTTGTCCGATTCACCTG-
G-3′) was cloned into pSilencer 2.0-U6 (Ambion) and
subcloned into the pE1sp1A vector. pE1sp1A-U6-
shZBTB2 vector and the adenovirus vector vmdl324Bst
were linearized by restriction enzyme digestion. Linearized
pE1sp1A-U6-shZBTB2 was co-transformed into E. coli
BJ518 with vmdl324Bst for homologous recombination.
Homologous recombinant adenoviral plasmid was di-
gested with PacI and transfected into HEK293 cells to
generate the adenovirus expressing siRNA against ZBTB2
mRNA(dl324-shZBTB2).
Effect of ZBTB2 on tumor growth in vivo
U343 glioblastoma tumor cells were implanted under the
abdominal skin of female BALB/c mice. Once tumors had
reached 100–120 mm3 in volume, mice were injected intra-
tumorally five times at 2-day intervals with either control
dl324 or dl324-shRNA ZBTB2 viruses (2 × 108 PFU). Tu-
mor growth was monitored by measuring the length and
width of the tumor three times a week using a caliper. Tu-
mor volume = 0.523Lw2, where L is length and w is width
in mm.
Immunohistochemical analyses of human glioblastoma tis-
sues
Formaldehyde-fixed, paraffin-embedded glioblastoma tis-
sue sections were obtained from Dr Se-Hoon Kim of the
Department of Pathology, Yonsei University School of
Medicine. DAB immunohistochemical (IHC) staining was
done according to the manufacturer’s instructions (VEC-
TASTAIN ABC Kit, Vector Laboratories) after incubating
with anti-ZBTB2, anti-RelA/p65 and anti-PDK4 antibod-
ies overnight at 4◦C.
Statistical analysis
Student’s t-test was used for the statistical analyses.P-values
of <0.05 were considered statistically significant.
RESULTS
The RelA/p65 promoter is activated by Sp1 and a specific
proximal GC-rich element (bp, −30 to −1) is important for
transcriptional initiation/activation of the RelA/p65 gene by
Sp1
Promoter analysis of the RelA/p65 gene for potential tran-
scription factor binding sites using the MacVector program
revealed that the promoter lacks a TATA consensus se-
quence and is GC-rich (71%) in a 445-bp region (bp, +44
to −401) from the transcription start point. The promoter
region contains more than 14 potential Sp1-binding GC-
boxes (bp, +25 to +34, +1 to +17, −1 to −30, −39 to
−51, −82 to −95, −108 to −115, −177 to −192, −200 to
−218, −240 to −262, −279 to −289, −300 to −309, −322
to −336, −361 to −378, −385 to −394) (Supplementary
Figure S1). Sp1-binding GC-boxes cover theRelA/p65 pro-
moter region extensively, suggesting that Sp1 might be a
critical transcription regulator of RelA/p65 transcription.
Accordingly, we investigated whether the RelA/p65 gene is
regulated by Sp1 at the transcriptional level. Knockdown of
Sp1 mRNA potently decreased RelA/p65 expression both
at the mRNA and protein levels (Figure 1A and B).
To identify the RelA/p65 promoter regulatory elements
that mediate transcriptional activation by Sp1, HEK293
cells were co-transfected with Sp1 expression vector and
variousRelA/p65 promoter reporter gene fusion constructs
differing in the length of the 5′ upstream regulatory se-
quence (Figure 1C). The pRelA/p65-Luc −401(bp, −30
to +44) reporter construct that retained almost all of the up-
stream regulatory sequence (except the promoter GC-box
#3) was also tested. Transient transfection and transcrip-
tion assays of various pRelA/p65-Luc plasmids showed
that Sp1 could induce RelA/p65 primarily by acting on its
proximal minimal promoter. Deletion of the promoter re-
gion down to −1 and deletion of a −30 to +44 region abol-
ished transcriptional activation by Sp1. The pRelA/p65-
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Figure 1. Sp1 activates transcriptional initiation/activation of RelA/p65 via a proximal promoter GC-rich element (bp, −30 to −1). (A, B) RT-qPCR
and western blot analysis of RelA/p65 expression. Knockdown of Sp1 mRNA resulted in a potent decrease in RelA/p65 expression at both the mRNA
and protein levels. *P < 0.05. (C) Transient transfection and transcription assays, and identification of a cis-regulatory element critical in transcriptional
initiation/activation of RelA/p65 by Sp1 in HEK293 cells. The structures of various pGL2-RelA/p65-Luc constructs are shown on the left. +1 (Tsp),
transcription start point. Potential Sp1-binding GC-boxes are indicated (open circles, as analyzed by MacVector program). The data presented are the
average of three independent assays. Luciferase activity was normalized to total protein concentration. Bars indicate standard deviation. *P < 0.05,
statistically significant.
Luc −135, −102 and −47 constructs showed nearly iden-
tical transcriptional activation by Sp1, suggesting that the
Sp1 GC-boxes at bp −30 to −1 may be important for tran-
scriptional initiation and/or activation. The pRelA/p65-
Luc −401, −333, −253 and −191 constructs showed simi-
lar transcriptional activation by Sp1. Although overall tran-
scription levels of these constructs appeared higher than
those of the shorter constructs −135, −102, and −47, the
differences were not statistically significant (Figure 1C).
Alternatively, knockdown of Sp1 expression potently de-
creased transcription of the RelA/p65 promoter in most of
the constructs, but not in the pRelA/p65-Luc +1 construct
(Supplementary Figure S2B). These data suggest that Sp1
can activate RelA/p65 gene transcription primarily by act-
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ing on the proximal promoter element containing GC-box
#3 (bp, −30 to −1).
ZBTB2 interacts directly with transcription factor Sp1 and
represses the RelA/p65 promoter by acting on the proximal
GC-rich element (bp, −30 to −1)
Previously, we showed that ZBTB2 interacts with Sp1 di-
rectly (7). Because the RelA/p65 gene is activated by Sp1,
we tested whether the interaction between ZBTB2 and Sp1
is important for transcriptional regulation of RelA/p65. To
that end, we found that the pGL2-RelA/p65-Luc (−47 bp)
construct was activated by Sp1; deletion of further down-
stream regions resulted in no transcriptional activation by
Sp1. Using the same constructs, we next investigated possi-
ble regulatory relationships between Sp1 and ZBTB2. As
expected, Sp1 activated the RelA/p65 promoter by 1.8-
fold and transcriptional activation by Sp1 was potently re-
pressed by ZBTB2 in the absence or presence of Sp1 co-
expression (70–80%) (Figure 2A). In contrast, the pGL2-
RelA/p65-Luc (−401(−30 to+44)) construct, with a dele-
tion of the proximal promoter, was neither activated by Sp1
nor repressed by ZBTB2, suggesting that the minimal pro-
moter region (containing GC-box #3, −30 to −1 bp) is
important for transcription initiation and activation of the
RelA/p65 gene by Sp1, and repression by ZBTB2. Conse-
quently, the GC-box #3 element residing in the region from
−30 to −1 bp may be the target of transcriptional repres-
sion by ZBTB2.
ZBTB2 represses transcription of endogenousRelA/p65 gene
expression in human HEK293 cells
Using RT-qPCR and western blot analysis, we investigated
whether ectopic ZBTB2 overexpression or knockdown af-
fected transcription of the endogenous RelA/p65 gene. In
human HEK293 cells, ectopic ZBTB2 significantly down-
regulated RelA/p65, while ZBTB2 knockdown enhanced
RelA/p65 expression at the protein level (Figure 2B). Ec-
topic ZBTB2 expression repressed RelA/p65 transcription
by 0.4- to 0.5-fold, and knockdown of ZBTB2 increased
transcription of the RelA/p65 gene by 2.5-fold (Figure 2C).
These data further suggest that ZBTB2 represses RelA/p65
transcription by acting on its proximal promoter GC-box
element (bp, −30 to −1).
ZBTB2 and Sp1 directly bind GC-boxes, including GC-box
#3 (bp,−32 to−21) in the proximalRelA/p65 promoter, and
the two proteins show identical DNase I footprinting patterns
Because Sp1 activates transcription of the RelA/p65 gene
and ZBTB2 represses transcriptional activation by Sp1, we
used DNase I footprinting to investigate DNA binding of
Sp1 and ZBTB2 to five Sp1 footprinting regions (bp, +58
to +68; bp, +21 to +24; bp, −32 to −21; bp, −63 to −49;
bp, −93 to −83) in the RelA/p65 proximal promoter. In-
triguingly, although comparison of amino acid sequences of
the zinc finger DNA-binding domains of ZBTB2 and Sp1
showed no apparent sequence homology, ZBTB2 bound to
the exactly same regions recognized by Sp1 (Figure 3A).
Interestingly, the pGL2-RelA/p65-Luc (−47 bp) construct,
which showed transcriptional activation by Sp1 and repres-
sion by ZBTB2, contains two 11 base pair and one short
four base pair DNase I footprinting regions (Figure 3B).
Considering that there was no transcriptional regulation of
pGL2-RelA/p65-Luc (401(−30 to +44)) lacking DNase I
footprinting region 3 (containing GC box #3) by Sp1 and
ZBTB2 (Figure 2A), this region might be a key regulatory
element important in transcription initiation and activation
by Sp1 and also repression by ZBTB2 (Figure 3B).
ZBTB2 and Sp1 directly bind the GC-box #3 of the
RelA/p65 promoter, and ZBTB2 blocks Sp1 binding
We next analyzed the molecular events involving DNA in-
teractions by Sp1 and ZBTB2 at the RelA/p65 proximal
minimal promoter because the region contains the key reg-
ulatory footprinting element GC-box #3 (bp, −32 to −21),
which may be essential for transcriptional initiation and ac-
tivation of the RelA/p65 gene by Sp1, and repression by
ZBTB2. Using electrophoretic mobility shift assays (EM-
SAs), we further investigated whether recombinant GST-
ZFDBD-ZBTB2 and Sp1 protein could bind the GC-box
#3 probe flanking footprinting region 3 (bp, −32 to −21),
showing that ZBTB2 and Sp1 directly interact with each
other (SupplementaryFigure S3), and bothZBTB2 and Sp1
bind to the GC-box #3 of the RelA/p65 promoter (Figure
4A). Oligonucleotide pull-down assays of whole cell lysates
transfected with empty pcDNA3 or ZBTB2 expression vec-
tors also showed that Sp1 andZBTB2bound toGC-box#3,
where Sp1 binding was significantly decreased by the pres-
ence of ZBTB2, but not at GC-box #7 (bp, −177 to −192)
or GC-box #12 (bp,−322 to−336) (Figure 4B). These data
indicate that ZBTB2 might directly block Sp1 binding to
GC-box #3 by binding competition.
We also investigated whether ZBTB2 could block Sp1
binding atGC-box #3 byChIP ofHEK293 cells transfected
with Sp1- and increasing amounts of ZBTB2-expression
vectors. When ectopic ZBTB2 binding increased, Sp1 bind-
ing to the region decreased in a dose-dependent manner
(Figure 4C). Alternatively, we also used ChIP to investigate
whether knockdown of ZBTB2 expression could increase
Sp1 binding to the region flanking GC-box #3 (Figure 4D
and E). ChIP-re-ChIP assays showed that ectopic ZBTB2
decreased Sp1 binding to the element (Figure 4F).
Furthermore, to even more firmly establish the impor-
tance of GC-box #3 in RelA/p65 transcriptional initiation
and activation by Sp1 and repression by ZBTB2, we made a
reporter construct with amutation introduced at the core of
GC-box #3 (CCCGGCCCC to TTTAATTTT). Transient
transcription assays showed that ZBTB2 potently downreg-
ulatesRelA/p65 promoter having thewild-type, but notmu-
tant, promoter GC-box #3. The mutation had no effect,
however, on RelA/p65 transcriptional activation by Sp1,
suggesting that GC-box #2 and/or #1might also be impor-
tant in transcription initiation and activation by Sp1 (Fig-
ure 4G).
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Figure 2. ZBTB2 potently represses endogenous RelA/p65 expression in HEK293 cells by acting on the proximal GC-rich promoter element (bp, −30
to −1). (A) Transient transfection and transcription assays in HEK293 cells. HEK293 cells were co-transfected with the pGL2-RelA/p65-Luc reporter
constructs indicated (−47; −401(−30 to +44)) and Sp1 and/or ZBTB2 expression vectors. Luciferase activity was measured 48 h after transfection and
normalized to total protein concentration. Bars represent standard deviations. *P< 0.05. (B) Western blot analysis of regulation of endogenous RelA/p65
expression by ZBTB2. HEK293 cells were transfected with pcDNA3 or pcDNA3-ZBTB2 expression plasmid or ZBTB2 siRNA. Whole cell extracts were
separated by SDS-PAGE and analyzed using the antibodies indicated. GAPDH, control. (C) RT-qPCR analysis of regulation of endogenous RelA/p65
mRNA expression by ZBTB2. Cells were treated as in (B). Total mRNAwas isolated from cells and the levels ofZBTB2 andRelA/p65mRNA determined
by RT-qPCR and normalized to 18S ribosomal RNA. *P < 0.05.
ZBTB2 bound to the RelA/p65 proximal promoter GC-box
#3 recruits the NCoR–HDAC complex and deacetylates his-
tone H3 and H4 to repress RelA/p65 transcription
As shown Figure 4, ZBTB2 decreased Sp1 binding at the
RelA/p65 proximal promoter. Using qChIP-PCR assays,
we examined one possible mechanism of ZBTB2 repres-
sion, recruitment of the co-repressor NCoR-HDAC com-
plex to the RelA/p65 proximal promoter GC-box #3 ele-
ment and deacetylation of histones around its transcrip-
tion initiation point. HEK293 cells were co-transfectedwith
increasing amounts of either pcDNA3-ZBTB2 expression
vector or ZBTB2 siRNA.These studies showed that ZBTB2
increased the recruitment of NCoR to the proximal pro-
moter region to deacetylate histones H3 and H4 in a dose-
dependent manner (Figure 5A). Additionally, knockdown
of ZBTB2 strongly decreased NCoR recruitment to the re-
gion, resulting in increased acetylation of histones H3 and
H4 (Figure 5B). These changes in epigenetic markers of hi-
stones around the transcription initiation sites suggest that
ZBTB2 represses RelA/p65 transcription by nucleosome
compaction around the promoter region critical in tran-
scription.
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Figure 3. DNase I footprinting assays. ZBTB2 and Sp1 identically bind to five GC-box elements including GC-box #3 (bp, −32 to −21) of the RelA/p65
proximal promoter. (A) DNase I footprinting of the RelA/p65 promoter with recombinant Sp1 (100, 300, 900 ng) and His-ZBTB2 (1, 3, 9 g). Left, sense
strand short run; right, sense strand long run. G and G+A indicate Maxam and Gilbert sequencing reactions of the 32P-labeled promoter DNA fragment
(246 bp). N, control reaction without Sp1 and ZBTB2. (B) Summary of DNase I footprinting sequences. Footprinting regions (1–5) are indicated in black.
The transcription start point (+1, Tsp) is marked by an arrow.
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Figure 4. ZBTB2 and Sp1 directly bind to GC-box #3 in the proximal RelA/p65 promoter and ZBTB2 decreases Sp1 binding at the element in vitro
and in vivo. (A) Electrophoretic mobility shift assays (EMSAs). The 32P-labeled GC-box #3 probe was incubated with recombinant Sp1 (100 ng) or GST-
ZFDBD-ZBTB2 (1 g), in the presence or absence of cold competitor probe (100x) or anti-Sp1 or anti-ZBTB2 antibodies, and the mixtures separated by
4% non-denaturing PAGE and analyzed by autoradiography. (B) Oligonucleotide pull-down assays of ZBTB2 and Sp1 binding. Structure of the RelA/p65
promoter with GC-box #3 and locations of ChIP oligonucleotide primers spanning the GC-box #3 are indicated above. GC-box #7 and #12 elements
were used as controls. The transcription start point (Tsp, +1) is indicated by an arrow. HEK293 cells were transfected with pcDNA3 or pcDNA3-ZBTB2
plasmids and harvested after 48 h. Biotinylated oligonucleotide probes including GC-box #3 linked to streptavidin agarose beads were incubated with the
cell lysates. The precipitates were then analyzed by western blotting using the antibodies indicated. GAPDH, control. (C, D) ChIP assays of ZBTB2 and
Sp1 binding at the proximal promoter region flanking GC-box #3. HEK293 cells were transfected with increasing amounts of ZBTB2 expression vector or
combinations of three distinct anti-ZBTB2 siRNAs. Chromatin was immunoprecipitated with the antibodies indicated and analyzed by qRT-PCR. IgG,
negative control. *P < 0.05. **P = 0.06. (E) Knockdown of ZBTB2 expression and western blot analysis. HEK293 cells were transfected with an siRNA
mixture. GAPDH, control. N.C., negative control scrambled siRNA. (F) ChIP-reChIP assay of ZBTB2 and Sp1 binding to the RelA/p65 promoter.
HEK293 cells were transfected with pcDNA3-ZBTB2 and immunoprecipitated with ZBTB2 (first) or IgG and Sp1 antibodies (second). (G) Transient
transfection and transcription assays. pRelA/p65-Luc −47-bp wild-type or mutant reporter constructs were co-transfected with control or ZBTB2 or Sp1
expression vector into HEK293 cells. Luciferase activity was measured 48 h after transfection. The data presented are the average of three independent
assays. Luciferase activity was normalized to total protein concentration. *P < 0.05.
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Figure 5. ZBTB2 bound at the proximal GC-box #3 of endogenous RelA/p65 recruits the NCoR–HDAC complex and deacetylates histones H3 and H4.
ChIP assay of acetylated histones H3 and H4 and corepressor NCoR binding at the proximal promoter flanking GC-box #3 of the endogenous RelA/p65
gene. HEK293 cells were transfected with increasing amounts of ZBTB2 expression vector (A) or ZBTB2 siRNA (B). *P < 0.05. **P = 0.06. Chromatin
was immunoprecipitated with the antibodies indicated and analyzed by qRT-PCR. *P < 0.05.
ZBTB2 represses transcriptional activation of the NF-B re-
sponsive reporter plasmid pNF-B-Luc by TNF
BecauseRelA/p65 is crucial forNF-B-mediated transcrip-
tion, we examined whether ZBTB2 might affect reporter
expression of pNF-B-Luc in cells stimulated by TNF
(Figure 6A). ZBTB2 alone repressed transcription of pNF-
B-Luc, while TNF treatment increased luciferase expres-
sion 3-fold, which was repressed by ZBTB2 to the levels
of the control (Figure 6B). Knockdown of ZBTB2 dere-
pressed transcription by 5-fold. TNF treatment potently
activated transcription of the reporter gene 43-fold (Figure
6C). These results suggest that ZBTB2 potentially plays a
major role in suppressing theNF-B target gene expression.
Accordingly, we tested whether expression of endogenous
NF-B target genes such as IL-1, -6 and -8 was affected by
ZBTB2. Ectopic ZBTB2 expression repressed interleukin
genes, while knockdown of ZBTB2 derepressed interleukin
genes, particularly IL-1 (Supplementary Figure S4A and
B).
Because the POZ domain of ZBTB2 is important in tran-
scriptional repression (7), we next investigated if the do-
main is also important in transcription of pNF-B-Luc in
HEK293 cells. While ZBTB2 potently repressed reporter
expression, ZBTB2POZ (lacking the POZ domain) very
weakly repressed reporter expression, suggesting the impor-
tance of the POZ domain in transcriptional repression (Fig-
ure 6D).
Furthermore, we investigated whether ZBTB2 influenced
transcription of the endogenousRelA/p65 gene in HEK293
cells treated with TNF. While the mRNA levels of ZBTB2
and Sp1 remained the same or slightly increased, TNF
treatment increased RelA/p65 mRNA expression. By con-
trast, endogenous RelA/p65 expression was potently re-
pressed by ZBTB2 both in the absence or presence of TNF
(Figure 6E and F). These data demonstrate that ZBTB2 is a
transcriptional repressor of the endogenous RelA/p65 gene
in quiescent or TNF-stimulated cells.
Previous studies show that translocation of NF-B from
cytoplasm into nucleus is important in NF-B signaling
cascade. To determine the effect of ZBTB2 and Sp1 on
translocation of RelA/p65, we investigated amount of nu-
clear RelA/p65 protein by western blot analysis of cytosol
and nuclear cell fractions. While ectopic Sp1 increases cyto-
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Figure 6. ZBTB2 represses transcriptional activation of pNF-B-Luc and the RelA/p65 gene by TNF in HEK293 cells. (A) Structure of pNF-B-Luc.
Filled black box, NF-B responsive element; Tsp, transcription start point (+1). (B, C) Transient transcription assays in HEK293 cells transfected with
pNF-B-Luc and pcDNA3 or pcDNA3-ZBTB2 plasmids or ZBTB2 siRNA. Cells were treated with TNF (20 ng/ml) for 12 h. Error bars, standard devi-
ations; N.C., negative control (scrambled siRNA). (D) Transient transcription assays. HEK293 cells were co-transfected with pNF-B-Luc and pcDNA3-
ZBTB2 or pcDNA3-ZBTB2POZ. TNF treatment was as described above. Luciferase activity was analyzed as in (B) and (C). (E) RT-qPCR analysis of
RelA/p65 and Sp1 mRNA in TNF-treated HEK293 cells transfected with ZBTB2 expression vector. Cells were treated with TNF for 12 h. The data
were normalized to 18S ribosomal RNA. (F) Western blot analysis of RelA/p65 and Sp1 expression in HEK293 cells treated as in (E). ZBTB2, RelA/p65,
Sp1 and GAPDH protein in total cell lysates were analyzed using the antibodies indicated. GAPDH, control.
plasmic and nuclear RelA/p65, ectopic ZBTB2 decreases
cytoplasmic and nuclear RelA/p65. Moreover, we tested
whether ectopic ZBTB2 changes RelA/p65 associated with
IB- by co-immunoprecipitation with an anti-RelA/p65
antibody and western blot analysis with an anti-IB- an-
tibody. When ZBTB2 was overexpressed, more IB- inter-
acted with RelA/p65, suggesting that ZBTB2 may decrease
nuclear RelA/p65 by increasing cytosolic RelA/p65-IB-
interactions (Supplementary Figure S5A and B).
We also analyzed the temporal changes in expression of
RelA/p65 and ZBTB2 in the HEK293 cells treated with
TNF. Expression of RelA/p65 was increased over 60
min and interestingly, ZBTB2 expression was decreased
in a manner negatively correlates with RelA/p65 expres-
sion. It appears that TNF treatment activates NF-B re-
sponse gene transcription by de-repressing RelA/p65 ex-
pression through decreasing ZBTB2 expression over a 60-
min period. Once, NF-B responsive gene expression is ac-
complished, ZBTB2 expression may be restored to repress
RelA/p65 expression, as shown in Figure 6E and F, at 12 h
post TNF treatment (Supplementary Figure S6).
ZBTB2 decreases PDH activity by increasing PDK4 expres-
sion
PGC1 activates PDK4 expression by binding anNR bind-
ing site within thePDK4 promoter. RelA/p65 directly inter-
acts with PGC1 and inhibits PDK4 transcriptional activa-
tion by PGC1 (36). Because ZBTB2 represses RelA/p65
transcription, ZBTB2 may increase PDK4 expression in-
directly by increasing unbound PGC1. Consequently, we
investigated whether ZBTB2 regulates endogenous PDK4
and PGC1 expression using western blot analysis. In hu-
man HEK293 cells transfected withZBTB2, PDK4 expres-
sion increased, with no change in PGC1 expression (Fig-
ure 7A). Because more free PGC1 is available by downreg-
ulation of its binding partner RelA/p65 by ZBTB2, PGC1
may increasingly bind to the PDK4 promoter and activate
PDK4 transcription. Indeed, ChIP assays showed increased
PGC1 binding to thePDK4 promoter region-flankingNR
site in HEK293 cells transfected with pcDNA3-ZBTB2 ex-
pression vector, compared to the control (Figure 7B).
The PDH complex, a critical enzyme that converts pyru-
vate to acetyl coenzyme A (Ac-CoA), is a major regula-
tor of glucose metabolism. Because PDK4 inhibits PDH
activity by phosphorylation and ZBTB2 increase expres-
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Figure 7. ZBTB2 decreases PDH activity by increasing PDK4 expression (A) Western blot analysis of regulation of endogenous PDK4 expression by
ZBTB2. HEK293 cells were transfected with pcDNA3 or pcDNA3-ZBTB2 expression plasmid. Whole cell extracts were separated by SDS-PAGE and
analyzed using the antibodies indicated. GAPDH, control. (B) ChIP assays of PGC1 binding to the PDK4 proximal promoter region flanking a nuclear
receptor binding site (NR). HEK293 cells were transfected with ZBTB2 expression vector. Chromatin was immunoprecipitated with the antibodies indi-
cated and analyzed by PCR. IgG, negative control. IRS, FOXO1-binding element; NR, nuclear receptor binding element; Sp1RE, Sp1 binding element.
(C) PDH activity in HEK293 cells was measured using a coupled enzyme assay of the cell lysates. *P < 0.05. (D) Concentration of lactate produced by
HEK293 cells transfected with control or ZBTB2 expression vector was measured using lactate assay kits. Data were from two independent experiments.
*P < 0.05. (E) Western blot analysis of regulation of endogenous PDK4 expression by ZBTB2. HEK293 cells were transfected with siZBTB2 and/or
siRelA/p65 RNA. Whole cell extracts were separated by SDS-PAGE and analyzed using the antibodies indicated. GAPDH, control. (F, G) PDH activity
and lactate concentration in HEK293 cell lysates were measured using a coupled enzyme assay and lactate assay kit, respectively. HEK293 cells transfected
with siZBTB2 and/or siRelA/p65 RNA. Data were from three independent experiments. *P < 0.05.
sion of PDK4 via PGC1, we examined whether ZBTB2
could regulate PDH activity. Ectopic expression of ZBTB2
in HEK293 cells decreased PDH activity (Figure 7C). Fur-
thermore, we investigated whether decreased PDH activity
in cells with ectopic ZBTB2 expression affected lactate pro-
duction. Lactate assays showed that the concentration of
lactate was increased by ectopic ZBTB2 (Figure 7D).
We also examined whether PDK4 upregulation by
ZBTB2 was through repression of RelA/p65 expression
by a ‘loss of function’ approach in which ZBTB2 siRNA
and/or RelA/p65 siRNA were transfected into HEK293
cells. Those results showed PDK4 expression decreased by
ZBTB2 knockdown and increased by RelA/p65 knock-
down (Figure 7E). Moreover, ZBTB2 knockdown could
not decrease PDK4 expression in the absence of RelA/p65,
eventually resulting in increased PDH activity and de-
creased lactate production, which was not observed in the
cells with RelA/p65 knockdown (Figure 7F and G).
We also investigated whether ZBTB2 regulates RelA/p65
and PDK4 expression in other cell types. It has been pre-
viously shown that microRNA-149 downregulates ZBTB2
expression. In glioblastoma, ZBTB2 expression may be
rather high because microRNA-149 expression is low. Ac-
cordingly, we selected the U343 cell line, derived from
a glioblastoma, to investigate whether ZBTB2 regulates
RelA/p65 and PDK4 expression. In U343 cells, ZBTB2
repressed RelA/p65 transcription and eventually also in-
creased PDK4 expression similar to HEK293 cells. These
changes resulted in decreased PDH activity and increased
lactate concentration. We also confirmed that ZBTB2 in-
crease PDK4 expression via RelA/p65 inhibition, suggest-
ing that ZBTB2 may also act as a proto-oncogene in
glioblastoma (Supplementary Figure S7).
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Cancer cells or highly proliferative cells show low PDH
activity and thereby metabolic contribution of the TCA
cycle is compromised and glycolytic pathways supplement
their metabolic needs. Because ZBTB2 can reprogram cel-
lular glucose metabolism into the metabolic pattern similar
to that of cancer cells or highly proliferative cells, we ex-
amined whether ectopic ZBTB2 could stimulate tumor cell
proliferation in a mouse xenograft assay.
Those studies showed that the volume of tumors derived
from xenografted U343 glioblastoma cells was significantly
(47%) decreased by intra-tumoral injection of recombinant
adenovirus overexpressing ZBTB2 shRNA over a 31-day
period (Supplementary Figure S8A). These data suggest
that ZBTB2 may increase cell proliferation by shifting glu-
cose metabolic pathways to those used by cancer cells or
highly proliferative cells.
Other reported that ZBTB2 expression may be high in
glioblastoma tissues that express low levels of microRNA-
149 against ZBTB2 (11). Because ZBTB2 affects path-
ways from RelA/p65 down to lactate production, we
tested whether changes in RelA/p65 and PDK4 expres-
sion caused by high ZBTB2 expression were also observed
in glioblastoma by immunocytochemistry. Indeed, ZBTB2
and PDK4 expression in glioblastoma tissues was high,
while RelA/p65 expressionwas low, compared to that of the
control (Supplementary Figure S8B). These changes sug-
gest that a metabolic shift to glycolysis in cells with ectopic
ZBTB2 may also be applicable to glioblastoma.
DISCUSSION
NF-B is involved in a variety of cellular stress responses
and is also a key regulator of immune responses. Although
regulation of the activity of the RelA/p65 protein, a key
subunit of NF-B, is well known (16), the mechanisms of
RelA/p65 regulation at the transcriptional level, which may
be important for sustainedNF-B responses, remain largely
unknown. The RelA/p65 promoter is GC-rich (>71%) and
has many potential Sp1-binding sites, of which three have
been proposed to be important for increasing promoter ac-
tivity of the RelA/p65 gene (30). Here, we found that Sp1
activates transcription of the RelA/p65 gene (Figure 1).
ZBTB2 potently repressed transcriptional activation of
RelA/p65 by Sp1. The presence of ZBTB2 potently blocks
the DNA-binding activity of Sp1 and also nearly com-
pletely blocks transcription of a RelA/p65 reporter by Sp1
through the key regulatory element, GC-box #3 (Figures
2–4). We showed that molecular interactions between Sp1,
ZBTB2 and the GC-box regulated the expression levels of
RelA/p65. Specifically, ZBTB2 bound to theRelA/p65 pro-
moter and increased the recruitment of the NCoR–HDAC
complex to the RelA/p65 promoter region, which deacety-
lated histone H3 and H4 in a dose-dependent manner (Fig-
ure 5). Thus, ZBTB2may repressRelA/p65 by inhibition of
Sp1 binding and increased nucleosome compaction of the
RelA/p65 proximal promoter.
RelA/p65 not only acts as an NF-B subunit but
also plays a direct role in various biological processes.
Overexpression of RelA/p65 has been shown to activate
curcumin-induced apoptosis in HCT116 human colon can-
cer cells (37), and to maintain cellular senescence by
promoting DNA repair and genomic stability in pre-
neoplastic cells (38). Also, RelA/p65 can interact with
histone deacetylase/co-repressors (including HDAC1 and
HDAC2), resulting in gene repression (39). Thus, RelA/p65
may act either as a tumor suppressor or an oncoprotein, de-
pending on cellular contexts.
Because ZBTB2 is a transcriptional repressor of the
RelA/p65 gene, we investigated the effect of ZBTB2 on
NF-B responsive reporter gene expression activated by
TNF. ZBTB2 significantly decreased reporter expres-
sion of the pNF-B-Luc. Interestingly, transcription of
RelA/p65 increased 3.5-fold by TNF treatment (Figure
6). It is well known that TNF induces phosphorylation of
RelA/p65, but TNF effect on transcriptional activation of
theRelA/p65 gene is relatively unknown. There are a few re-
ports indicating that the mRNA level of the RelA/p65 gene
increases in response to TNF, but the mechanism remains
unknown (40,41).
In various cellular stress responses, the precise activation
and termination of NF-B activity and expression are im-
portant. The well-accepted mechanism for termination of
theNF-B response involves the resynthesis of IB proteins
induced by activated NF-B (28). Newly synthesized IB
enters the nucleus, releases NF-B from the DNA and relo-
calizes NF-B to the cytosol (29). Additionally, acetylation
of RelA/p65 has been demonstrated to decrease its DNA-
binding affinity (28), and post-translational modifications
of RelA/p65 by HATs or HDACs influence termination of
the NF-B response (39). Our data showed that ZBTB2 po-
tently decreases NF-B expression both in the presence or
absence of TNF. ZBTB2, as a transcriptional repressor,
keeps theRelA/p65 gene silent. This is the first report show-
ing how the expression of theRelA/p65 gene, a critical com-
ponent of NF-B, is repressed by ZBTB2 at the transcrip-
tional level, and how de novo repression of RelA/p65 gene
by ZBTB2 is deregulated by NF-B-activating signals such
as TNF (Figure 6). ZBTB2, as a repressor of transcrip-
tion, may regulate various biological processes controlled
by NF-B such as apoptosis, cell adhesion, immunity and
inflammation.
The PDH complex converts pyruvate into acetyl-CoA,
the first substrate used in the TCA cycle. Regulation of
PDH expression and activity is important for metabolism
of the pyruvate that derives from glycolysis and accordingly,
for glucose metabolism (42). Expression of PDK4, a nega-
tive regulator of the PDH complex, is regulated by diverse
factors such as ERR , C/EBP, FOXO1 and PGC1,
both transcriptionally and post-transcriptionally (35,43–
44). PDK4 is highly expressed in the liver, heart and skeletal
muscle, and is also upregulated in cancer cells.
Interestingly, cells overexpressing the oncoprotein
ZBTB2 proliferate more rapidly (7). Consequently, we
hypothesize that ZBTB2 may reprogram cellular metabolic
pathways to favor rapid cell proliferation, similar to cancer
cell metabolic pathways. PGC1, an activator of PDK4
transcription, directly interacts with RelA/p65; that in-
teraction limits the amount of PGC1 available to bind
the promoter of PDK4. Accordingly, by transcriptional
repression of RelA/p65, ZBTB2 indirectly increases PDK4
expression (via increased unbound PGC1), leading to
inhibition of PDH and attenuated glucose metabolic pro-
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Figure 8. Hypothetical model of transcriptional repression of RelA/p65 by ZBTB2, resulting in a glucose metabolism switch. (A) RelA/p65 proximal
promoter (up to −401 bp) is highly GC-rich and has many potential Sp1 binding GC-boxes (as many as 14). Among the potential Sp1-binding GC-boxes,
GC-box #3 is particularly important. The element is bound by Sp1 relatively strongly and plays a critical role in transcriptional initiation and activation
by Sp1. ZBTB2 interacts with Sp1 and affects Sp1 binding activity or competes with Sp1 to bind GC-box #3. ZBTB2 recruits the NCoR co-repressor
complex to repress transcription by histone compaction. (B) ZBTB2 switches glucose metabolism to favor glycolysis over the TCA cycle by indirectly
increasing PDK4 expression. Repression of RelA/p65 expression by ZBTB2 frees PGC1 to bind and activate the PDK4 promoter to eventually increase
PDK4 expression. PDK4 inhibits PDH activity, attenuating glucose metabolism through the TCA cycle. ZBTB2 also indirectly increases pyruvate and
lactate production, indicating activation of glycolysis. Thus, ZBTB2 may reprogram glucose metabolic pathways similar to those in cancer cells or highly
proliferative cells.
cessing via the TCA cycle. The molecular events triggered
by overexpressed ZBTB2 may cause metabolic switching to
favor glycolysis over the TCA cycle, a metabolic feature of
cancer cells (45,46). This conjecture was supported by our
finding a negative correlation between PDH activity and
PDK4 expression and lactate (Figure 7 and Supplementary
Figure S7). Thus, metabolic reprogramming may be one of
the features important for rapid proliferation of cells with
ectopic ZBTB2 (Figure 8).
Proliferating cells use aerobic glycolysis to meet their
metabolic needs other than only ATP (45). ZBTB2 not only
controls the genes of the p53 pathway such as CDKN1A
to increase cell proliferation (7), but also to reprogram
metabolic pathways favoring glycolysis to provide resources
including ATP, ribose and glycerol for nucleotide, amino
acid and lipid biosynethesis, and NADPH for rapid cell
proliferation, at the cost of massive glucose intake (45,46).
Overall, our results suggest that the proto-oncoprotein
ZBTB2 may stimulate cell proliferation through indirect
regulation of PDK4 expression via transcriptional repres-
sion of RelA/p65 (41).
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